Press Resease

Therapeutic Vaccines Market - Global Industry Analysis

Therapeutic Vaccines Market By Products (Addiction Vaccines, Autoimmune Disease Vaccines, Infectious Disease Vaccines And Neurological Disease Vaccines) And By Technology (Autologous Vaccine And Allogeneic Vaccine): Global Industry Perspective, Comprehensive Analysis And Forecast,2020 – 2028

Published Date: 20-Aug-2021 Category: Healthcare Report Format : PDF Pages: 145 Report Code: ZMR-1220 Status : Published

The global Therapeutic Vaccines Market accounted for USD 35.1 Billion in 2020 and is expected to reach USD 84.3 Billion by 2028, growing at a CAGR of around 10.7% between 2021 and 2028.

Description

Market Overview     

The global Therapeutic Vaccines Market accounted for USD 35.1 Billion in 2020 and is expected to reach USD 84.3 Billion by 2028, growing at a CAGR of around 10.7% between 2021 and 2028.      

Increased awareness regarding the potential value of vaccination within the developed, developing, and under-developed regions of the world is one of the major factors driving the therapeutic vaccine market. Other factors that are driving the market growth include favorable government funding for vaccine development, the rising prevalence of diseases, and a rise in R&D expenditure of the businesses. Major governmental and humanitarian organizations have taken up a lively interest in curbing the diseases prevented by vaccines and vaccinating the utmost number of infants and adults as possible, which led to the adoption of the latest products and provide strategies and therefore the formation of the donor market, that accounts for the most important marketplace for vaccines, in terms of dosage, globally.  

Global Therapeutic Vaccines Market Size

COVID-19 Impact Analysis  

The global Therapeutic Vaccines Market has witnessed growth during the pandemic. This is mainly attributed to the fact that the COVID-19 pandemic situation has led to the rise in demand for public health surveillance and clinical care. However, the rising difficulty in health care delivery has slightly challenged the market in 2020. The growth of the global Therapeutic Vaccines Market size is estimated based on the COVID-19 outbreak. Various scenarios have been analyzed based on inputs from various secondary sources and the current data available about the situation.

Growth Factors

The global therapeutic vaccines market is majorly fostered by increasing occurrences of chronic diseases like HIV and cancer everywhere in the world. Other factor includes growing funds from the government for R&D of vaccines paired with technological advancements. For instance, in April 2018, the Four-strain vaccine Influvac Tetra (dubbed as a quadrivalent vaccine,) developed by Mylan was made available in New Zealand. Nonetheless rising to specialize in customized medicine paired with the need for effective therapy are expected to reveal the new opportunities for the development therapeutic vaccines market within the forecast period. Additionally, elevating job opportunities are set to foster the event of the therapeutic vaccines market.

Report Scope:  

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Segment Analysis Preview  

Based on product type, the therapeutic vaccines market is divided into autoimmune disease vaccines, addiction vaccines, neurological disease vaccines, and infectious disease vaccines. The autoimmune disease vaccine section is likely to develop at the quickest rate in the therapeutic vaccines market shortly. The therapeutic vaccines market is divided based on technology into allogeneic vaccines and autologous vaccines.

Regional Analysis Preview  

North America, followed by Europe is probably going to remain the dominating area within the near future. The requirement for therapeutic vaccines was uppermost in North America particularly within the U.S. Asia Pacific is probably going to be the moderate developing area during the forecast period in the therapeutic vaccines market. Furthermore, Latin America and therefore the Middle East & Africa also are likely to point out reasonable development for the therapeutic vaccines market within the coming years.

Global Therapeutic Vaccines Market Share

Key Market Players & Competitive Landscape

Some of the key players in the therapeutic vaccines market include Valeant Pharmaceuticals, BioVex, Inc., Inovio Pharmaceuticals, Inc., Immunocellular Therapeutics, Ltd., Agenus Inc., GlaxoSmithKline plc., Pfizer Inc., Novartis AG, Argos Therapeutics, Bavarian Nordic, Transgene, Galena Biopharma, and Vaccinogen, Inc. among others.

Global Therapeutic Vaccines Market Regional Analysis

The global Therapeutic Vaccines Market is segmented as follows:

By-Products

  • Addiction Vaccines
  • Autoimmune Disease Vaccines
  • Infectious Disease Vaccines
  • Neurological Disease Vaccines

By Technology

  • Autologous vaccines 
  • Allogeneic vaccines

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Product
        • 2.1.1.2. Market Attractiveness Analysis, Technology
        • 2.1.1.3. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Therapeutic Vaccines Market, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Therapeutic Vaccines Market – Product Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Product, 2020 & 2028
    • 4.2. Addiction Vaccines
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Autoimmune Disease Vaccines
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Infectious Disease Vaccines
      • 4.4.1. Market Size and Forecast, By Region (USD Billion)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.5. Neurulogical Disease Vaccines
      • 4.5.1. Market Size and Forecast, By Region (USD Billion)
      • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Therapeutic Vaccines Market – Tecchnulogy Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, Technology, 2020 & 2028
    • 5.2. Autulogous vaccines
      • 5.2.1. Market Size and Forecast, By Region (USD Billion)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Allogeneic vaccines
      • 5.3.1. Market Size and Forecast, By Region (USD Billion)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Therapeutic Vaccines Market – Regional Analysis
    • 6.1. Overview
      • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 6.2. North America
      • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.2.2. North America Market Revenue, By Product, 2016 – 2028
      • 6.2.3. North America Market Revenue, Technology, 2016 – 2028
      • 6.2.5. U.S.
        • 6.2.5.1. U.S. Market Revenue, By Product, 2016 – 2028
        • 6.2.5.2. U.S. Market Revenue, Technology, 2016 – 2028
      • 6.2.6. Canada
        • 6.2.6.1. Canada Market Revenue, By Product, 2016 – 2028
        • 6.2.6.2. Canada Market Revenue, Technology, 2016 – 2028
      • 6.2.7. Mexico
        • 6.2.7.1. Mexico Market Revenue, By Product, 2016 – 2028
        • 6.2.7.2. Mexico Market Revenue, Technology, 2016 – 2028
    • 6.3. Europe
      • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.3.2. Europe Market Revenue, By Product, 2016 – 2028
      • 6.3.3. Europe Market Revenue, Technology, 2016 – 2028
      • 6.3.5. Germany
        • 6.3.5.1. Germany Market Revenue, By Product, 2016 – 2028
        • 6.3.5.2. Germany Market Revenue, Technology, 2016 – 2028
      • 6.3.6. France
        • 6.3.6.1. France Market Revenue, By Product, 2016 – 2028
        • 6.3.6.2. France Market Revenue, Technology, 2016 – 2028
      • 6.3.7. U.K.
        • 6.3.7.1. U.K. Market Revenue, By Product, 2016 – 2028
        • 6.3.7.2. U.K. Market Revenue, Technology, 2016 – 2028
      • 6.3.8. Italy
        • 6.3.8.1. Italy Market Revenue, By Product, 2016 – 2028
        • 6.3.8.2. Italy Market Revenue, Technology, 2016 – 2028
      • 6.3.9. Spain
        • 6.3.9.1. Spain Market Revenue, By Product, 2016 – 2028
        • 6.3.9.2. Spain Market Revenue, Technology, 2016 – 2028
      • 6.3.10. Rest of Europe
        • 6.3.10.1. Rest of Europe Market Revenue, By Product, 2016 – 2028
        • 6.3.10.2. Rest of Europe Market Revenue, Technology, 2016 – 2028
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.4.2. Asia Pacific Market Revenue, By Product, 2016 – 2028
      • 6.4.3. Asia Pacific Market Revenue, Technology, 2016 – 2028
      • 6.4.5. China
        • 6.4.5.1. China Market Revenue, By Product, 2016 – 2028
        • 6.4.5.2. China Market Revenue, Technology, 2016 – 2028
      • 6.4.6. Japan
        • 6.4.6.1. Japan Market Revenue, By Product, 2016 – 2028
        • 6.4.6.2. Japan Market Revenue, Technology, 2016 – 2028
      • 6.4.7. India
        • 6.4.7.1. India Market Revenue, By Product, 2016 – 2028
        • 6.4.7.2. India Market Revenue, Technology, 2016 – 2028
      • 6.4.8. South Korea
        • 6.4.8.1. South Korea Market Revenue, By Product, 2016 – 2028
        • 6.4.8.2. South Korea Market Revenue, Technology, 2016 – 2028
      • 6.4.9. South-East Asia
        • 6.4.9.1. South-East Asia Market Revenue, By Product, 2016 – 2028
        • 6.4.9.2. South-East Asia Market Revenue, Technology, 2016 – 2028
      • 6.4.10. Rest of Asia Pacific
        • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Product, 2016 – 2028
        • 6.4.10.2. Rest of Asia Pacific Market Revenue, Technology, 2016 – 2028
    • 6.5. Latin America
      • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.5.2. Latin America Market Revenue, By Product, 2016 – 2028
      • 6.5.3. Latin America Market Revenue, Technology, 2016 – 2028
      • 6.5.5. Brazil
        • 6.5.5.1. Brazil Market Revenue, By Product, 2016 – 2028
        • 6.5.5.2. Brazil Market Revenue, Technology, 2016 – 2028
      • 6.5.6. Argentina
        • 6.5.6.1. Argentina Market Revenue, By Product, 2016 – 2028
        • 6.5.6.2. Argentina Market Revenue, Technology, 2016 – 2028
      • 6.5.7. Rest of Latin America
        • 6.5.7.1. Rest of Latin America Market Revenue, By Product, 2016 – 2028
        • 6.5.7.2. Rest of Latin America Market Revenue, Technology, 2016 – 2028
    • 6.6. The Middle-East and Africa
      • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.6.2. The Middle-East and Africa Market Revenue, By Product, 2016 – 2028
      • 6.6.3. The Middle-East and Africa Market Revenue, Technology, 2016 – 2028
      • 6.6.5. GCC Countries
        • 6.6.5.1. GCC Countries Market Revenue, By Product, 2016 – 2028
        • 6.6.5.2. GCC Countries Market Revenue, Technology, 2016 – 2028
      • 6.6.6. South Africa
        • 6.6.6.1. South Africa Market Revenue, By Product, 2016 – 2028
        • 6.6.6.2. South Africa Market Revenue, Technology, 2016 – 2028
      • 6.6.7. Rest of Middle-East Africa
        • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Product, 2016 – 2028
        • 6.6.7.2. Rest of Middle-East Africa Market Revenue, Technology, 2016 – 2028
  • Chapter No. 7: Therapeutic Vaccines Market – Industry Analysis
    • 7.1. Introduction
    • 7.2. Market Drivers
      • 7.2.1. Driving Factor 1 Analysis
      • 7.2.2. Driving Factor 2 Analysis
    • 7.3. Market Restraints
      • 7.3.1. Restraining Factor Analysis
    • 7.4. Market Opportunities
      • 7.4.1. Market Opportunity Analysis
    • 7.5. Porter’s Five Forces Analysis
    • 7.6. PEST Analysis
    • 7.7. Regulatory Landscape
    • 7.8. Technology Landscape
    • 7.9. Regional Market Trends
      • 7.9.1. North America
      • 7.9.2. Europe
      • 7.9.3. Asia Pacific
      • 7.9.4. Latin America
      • 7.9.5. The Middle-East and Africa
    • 7.10. Pricing Analysis
    • 7.11. Value Chain Analysis
    • 7.12. Downstream Buyers
    • 7.13. Distributors/Traders List
  • Chapter No. 8: Competitive Landscape
    • 8.1. Company Market Share Analysis – 2019
      • 8.1.1. Global Therapeutic Vaccines Market: Company Market Share, 2019
      • 8.1.2. Global Therapeutic Vaccines Market, Company Market Revenue, 2016 – 2019 (USD Billion)
      • 8.1.3. Global Therapeutic Vaccines Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 8.1.4. Global Therapeutic Vaccines Market: Radar Determinant Chart, 2019
    • 8.2. Strategic Developments
      • 8.2.1. Acquisitions & Mergers
      • 8.2.2. New Product Launch
      • 8.2.3. Regional Expansion
    • 8.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 9: Company Profiles
    • 9.1. Valeant Pharmaceuticals
      • 9.1.1. Company Overview
      • 9.1.2. Key Executives
      • 9.1.3. Product Portfolio
      • 9.1.4. Financial Overview
      • 9.1.5. Operating Business Segments
      • 9.1.6. Business Performance
      • 9.1.7. Recent Developments
    • 9.2. BioVex, Inc
    • 9.3. Inovio Pharmaceuticals, Inc.
    • 9.4. Immunocellular Therapeutics, Ltd.
    • 9.5. Agenus Inc.
    • 9.6. GlaxoSmithKline plc.
    • 9.7. Pfizer Inc.
    • 9.8. Novartis AG
    • 9.9. Argos Therapeutics
    • 9.10. Bavarian Nordic
  • Chapter No. 10: Marketing Strategy Analysis
    • 10.1. Marketing Channel
    • 10.2. Direct Marketing
    • 10.3. Indirect Marketing
    • 10.4. Marketing Channel Development Trends
    • 10.5. Economic/Pulitical Environmental Change
  • Chapter No. 11: Research Methodology
    • 11.1. Research Methodology
    • 11.2. Phase I - Secondary Research
    • 11.3. Phase II - Data Modeling
      • 11.3.1. Company Share Analysis Model
      • 11.3.2. Revenue Based Modeling
    • 11.4. Phase III - Primary Research
    • 11.5. Research Limitations
      • 11.5.1. Assumptions

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Product
FIG NO. 2. Market Attractiveness Analysis, Technology
FIG NO. 3. Market Attractiveness Analysis, By Region
FIG NO. 4. Global Therapeutic Vaccines Market Revenue, 2016 – 2028 (USD Billion)
FIG NO. 5. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 6. Market Revenue Share, By Product, 2020 & 2028 
FIG NO. 7. Global Therapeutic Vaccines Market for Addiction Vaccines, Revenue (USD Billion) 2016 – 2028
FIG NO. 8. Comparative Revenue Analysis of Therapeutic Vaccines Market for Addiction Vaccines, By Country, 2020 & 2028
FIG NO. 9. Global Therapeutic Vaccines Market for Autoimmune Disease Vaccines, Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of Therapeutic Vaccines Market for Autoimmune Disease Vaccines, By Country, 2020 & 2028
FIG NO. 11. Global Therapeutic Vaccines Market for Infectious Disease Vaccines, Revenue (USD Billion) 2016 – 2028
FIG NO. 12. Comparative Revenue Analysis of Therapeutic Vaccines Market for Infectious Disease Vaccines, By Country, 2020 & 2028
FIG NO. 13. Global Therapeutic Vaccines Market for Neurological Disease Vaccines, Revenue (USD Billion) 2016 – 2028
FIG NO. 14. Comparative Revenue Analysis of Therapeutic Vaccines Market for Neurological Disease Vaccines, By Country, 2020 & 2028
FIG NO. 15. Market Revenue Share, Technology, 2020 & 2028
FIG NO. 16. Global Therapeutic Vaccines Market for Autologous vaccines, Revenue (USD Billion) 2016 – 2028
FIG NO. 17. Comparative Revenue Analysis of Therapeutic Vaccines Market for Autologous vaccines, By Country, 2020 & 2028 
FIG NO. 18. Global Therapeutic Vaccines Market for Allogeneic vaccines, Revenue (USD Billion) 2016 – 2028
FIG NO. 19. Comparative Revenue Analysis of Therapeutic Vaccines Market for Allogeneic vaccines, By Country, 2020 & 2028
FIG NO. 20. Global Therapeutic Vaccines Market Revenue Share, By Region, 2020 & 2028
FIG NO. 21. North America Therapeutic Vaccines Market Revenue, 2016 - 2028 (USD Billion)
FIG NO. 22. Porter’s Five Forces Analysis for Global Therapeutic Vaccines Market
FIG NO. 23. PEST Analysis for Global Therapeutic Vaccines Market
FIG NO. 24. Pricing Analysis for Global Therapeutic Vaccines Market
FIG NO. 25. Value Chain Analysis for Global Therapeutic Vaccines Market
FIG NO. 26. Company Share Analysis, 2019
FIG NO. 27. Radar Determinant Chart, 2019
FIG NO. 28. Company Strategic Developments – Heat Map Analysis
FIG NO. 29. Medical Technologies, Inc. Business Segment Revenue Share, 2020 (%)
FIG NO. 30. Medical Technologies, Inc. Geographical Segment Revenue Share, 2020 (%)
FIG NO. 31. Market Channels
FIG NO. 32. Marketing Channel Development Trend
FIG NO. 33. Growth in World Gross Product, 2008-2018
FIG NO. 34. Research Methodology – Detailed View
FIG NO. 35. Research Methodology
 


List of Tables 

TABLE NO. 1. Global Therapeutic Vaccines Market: Snapshot
TABLE NO. 2. Quarterly Therapeutic Vaccines Market Revenue by Region, 2020
TABLE NO. 3. Quarterly Therapeutic Vaccines Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion) 
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion) 
TABLE NO. 6. Global Therapeutic Vaccines Market for Addiction Vaccines, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global Therapeutic Vaccines Market for Autoimmune Disease Vaccines, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 8. Global Therapeutic Vaccines Market for Infectious Disease Vaccines, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 9. Global Therapeutic Vaccines Market for Neurological Disease Vaccines, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 10. Global Therapeutic Vaccines Market for Autologous vaccines, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 11 Global Therapeutic Vaccines Market for Allogeneic vaccines, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 12. Global Therapeutic Vaccines Market Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 13. North America Therapeutic Vaccines Market Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 14. North America Therapeutic Vaccines Market Revenue, By Product, 2016 – 2028 (USD Billion)
TABLE NO. 15. North America Therapeutic Vaccines Market Revenue, Technology, 2016 – 2028 (USD Billion)
TABLE NO. 16. U.S. Therapeutic Vaccines Market Revenue, By Product, 2016 – 2028 (USD Billion)
TABLE NO. 17. U.S. Therapeutic Vaccines Market Revenue, Technology, 2016 – 2028 (USD Billion)
TABLE NO. 18. Canada Therapeutic Vaccines Market Revenue, By Product, 2016 – 2028 (USD Billion)
TABLE NO. 19. Canada Therapeutic Vaccines Market Revenue, Technology, 2016 – 2028 (USD Billion)
TABLE NO. 20. Mexico Therapeutic Vaccines Market Revenue, By Product, 2016 – 2028 (USD Billion)
TABLE NO. 21. Mexico Therapeutic Vaccines Market Revenue, Technology, 2016 – 2028 (USD Billion)
TABLE NO. 22. Drivers for the Therapeutic Vaccines Market: Impact Analysis
TABLE NO. 23. Restraints for the Therapeutic Vaccines Market: Impact Analysis
TABLE NO. 24. Major Buyers of Therapeutic Vaccines Market Market  
TABLE NO. 25. Distributors/Traders List of Therapeutic Vaccines Market Market
TABLE NO. 26. Global Therapeutic Vaccines Market, Company Market Revenue, 2016 – 2019 (USD Billion) 
TABLE NO. 27: Global Therapeutic Vaccines Market, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)   


 

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Therapeutic Vaccines market. Zion Research has collected and analyzed key data belong to the global Therapeutic Vaccines market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Therapeutic Vaccines across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Therapeutic Vaccines industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Therapeutic Vaccines market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and remember it, so that the immune system can recognize and destroy similar foreign organism in later encounters. Mainly there are two types of vaccines named preventive or prophylactic vaccines and therapeutic vaccines. A preventative vaccine is administered to a person free of the targeted infection, the immune system reacts by producing antibodies. Thus on the future encounter, these antibodies will recognize and destroy the foreign organism. On the other hand, therapeutic vaccines aim to increase the activity of the body’s natural defenses and are administered to the person afflicted with chronic infection or disease, against which naturally produced antibodies are ineffective. U.S. Food and Drug Administration approved the first therapeutic vaccine for cancer in 2010.

Cancer and HIV are the most common causes of death across the globe. The World Health Organization estimates, there were 14 million cancer cases worldwide and 8.2 million cancer-related deaths in 2012 and the number of cases are expected to increase about 24 million by 2035. As per the data published by WHO in global health observatory data, more than 70 million people have been infected with the HIV and about 35 million people have died since the beginning of the epidemic. Globally, 36.7 million people were living with HIV at the end of 2015. There are over 200 different types of cancer and each of which is classified by the type of cell that is initially affected. Various types of cancer include prostate cancer, blood cancer, lungs cancer etc. The treatment of cancer, HIV, and other severe diseases has become of prime importance owing to increasing burden of patients globally. Thus, novel non-invasive treatment strategies which include therapeutic vaccines are an attractive treatment option. Hence, global therapeutic vaccine market is expected to see positive growth in the coming years.

Global-Therapeutic-Vaccines-Market

Growing incidences of chronic diseases such as cancer, HIV, etc. are expected to be the major driver for the global therapeutic vaccines market. In addition, increasing funds from the government for research and development of vaccines coupled with technological advancements is expected to trigger the growth of global therapeutic vaccines industry in the coming years. However, high treatment cost and stringent regulatory policies coupled with high initial capital investment may pose the challenge to therapeutic vaccines market. Nevertheless, increasing focus on personalized medicine coupled with the need for effective treatment is expected to act as an opportunity for therapeutic vaccines market in near future.

Based on product type, therapeutic vaccines market has been segmented into addiction vaccines, autoimmune disease vaccines, infectious disease vaccines and neurological disease vaccines. Autoimmune disease vaccines segment is expected to grow at the fastest rate during the forecast period. The therapeutic vaccines market is segmented based on technology into autologous vaccines and allogeneic vaccines.

North America is expected to remain the dominant region over the forecast period. Increasing healthcare awareness is expected to boost the market in this region. Europe was the second largest market followed by Asia-Pacific. Asia-Pacific is expected to show fastest growth rate during the forecast period. The Middle East and Africa and Latin America are also expected to experience noticeable growth in the years to come.

Some of the key players in therapeutic vaccines market include Valeant Pharmaceuticals, BioVex, Inc., Inovio Pharmaceuticals, Inc., Immunocellular Therapeutics, Ltd., Agenus Inc., GlaxoSmithKline plc., Pfizer Inc., Novartis AG, Argos Therapeutics, Bavarian Nordic, Transgene, Galena Biopharma and Vaccinogen, Inc. among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The global Therapeutic Vaccines Market was valued at USD 35.1 Billion in 2020.

The global Therapeutic Vaccines Market is expected to reach USD 84.3 Billion by 2028, growing at a CAGR of 10.7% between 2021 to 2028.

The global therapeutic vaccines market is majorly fostered by increasing occurrences of chronic diseases such as HIV and cancer all over the globe.

North America is expected to remain the dominant region over the forecast period. North America followed by Asia-Pacific and Europe in terms of demand for the Therapeutic Vaccines Market Market.

Some of the key players in therapeutic vaccines market include Valeant Pharmaceuticals, BioVex, Inc., Inovio Pharmaceuticals, Inc., Immunocellular Therapeutics, Ltd., Agenus Inc., GlaxoSmithKline plc., Pfizer Inc., Novartis AG, Argos Therapeutics, Bavarian Nordic, Transgene, Galena Biopharma and Vaccinogen, Inc. among others.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed